Gastro Medical News about Pancreatectomy

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Use of Antiemetic Agents in Acute Gastroenteritis

3. 2008 Exclusive Survey—Earnings: Good news for primary care income

4. A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity

5. Medicare pay-for-reporting effort draws fire from frustrated doctors

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

The impact of obesity on outcomes following pancreatectomy for malignancy
Annals of Surgical Oncology, 06/29/09

Benns M et al. - In a study to determine the impact of obesity on operative outcomes, recurrence, and overall survival, it appears that obese pts had a higher rate and greater severity of postoperative complications, with increased operative blood loss. Obese pts did not demonstrate any significant difference in specific oncologic factors or survival. These data suggest an equivalent biologic effect of obesity on pancreatic cancer survival.

Methods

A review of a 1345 pt prospective hepatopancreaticobiliary database was performed to identify pts undergoing pancreatic resection for adenocarcinoma.
Obesity was defined as a body mass index (BMI) >30 kg/m2.
Data were analyzed using Wilcoxon, t test, and chi-square methods.
Survival was analyzed using log-rank analysis.
Postoperative complications were assessed using a 5-point scale.

Results

Of 306 pts undergoing pancreatic resection for pancreatic adenocarcinoma examined, 68 were defined as obese.
There was no significant difference seen in length of stay, operative time, tumor size, or node status.
Obese pts had a higher operative blood loss and were more likely to suffer postoperative complications (67.6% vs 50.4%).
There was no significant difference seen in disease-free survival or overall survival (22.1 mos for obese vs 25.6 mos for nonobese; 19.8 mos for obese vs 23.5 mos for nonobese).

<< Previous
Liver resection for metastatic colorectal cancer in the presence...

Next >>
The role of preoperative chemotherapy in patients with resectable...